Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) filed a Form 8-K on September 15, 2026, disclosing that its subsidiary Indivior UK Limited and Reckitt Benckiser Healthcare (UK) Limited entered into a Deed of Variation and Termination on September 9, 2026, accelerating the end of their Copacker Supply Agreement to January 15, 2027.

Key Highlights

  • Accelerated termination: The Copacker Supply Agreement, originally dated December 23, 2014 and amended March 29, 2019, will now end on January 15, 2027, earlier than previously scheduled.
  • Products covered: Reckitt Benckiser manufactures SUBOXONE® Tablets and SUBUTEX® Tablets for Indivior under the agreement.
  • New supplier identified: Indivior disclosed it has identified a new supplier, though obligations under the new agreement become enforceable only after validation of the new supplier's manufacturing process.
  • Additional production agreed: Reckitt Benckiser has agreed to manufacture additional units prior to the new termination date.
  • Costs described as non-material: The aggregate costs Indivior agreed to pay RB, including volume shortfall costs, asset disposal and depreciation recovery costs, redundancy costs, incentive costs, and potential third-party costs, are described as fixed or capped and "will not be material to the Registrant."
  • New supplier agreement also non-material: The agreement with the new supplier "is not expected to be material to Indivior Pharmaceuticals, Inc.," according to the filing.

Indivior and Reckitt Agree to End Tablet Manufacturing Arrangement Early

According to the filing, Indivior UK Limited and Reckitt Benckiser Healthcare (UK) Limited executed the Deed of Variation and Termination on September 9, 2026. The underlying Copacker Supply Agreement, under which Reckitt Benckiser manufactures SUBOXONE® Tablets and SUBUTEX® Tablets for Indivior, had been in place since December 23, 2014, with a prior amendment dated March 29, 2019. The deed moves the termination date forward to January 15, 2027, and the filing states the agreement "will remain in effect until the accelerated termination date."

The filing details the financial obligations Indivior accepted as part of the early termination. Indivior agreed to pay Reckitt Benckiser for costs resulting from ordering lower volumes than the agreement contemplated, as well as certain asset disposal and depreciation recovery costs, redundancy costs, incentive costs, and potential third-party costs. The registrant characterized the aggregate amount of these costs as "fixed or capped" and not material. In exchange, Reckitt Benckiser agreed to manufacture additional units before the new termination date.

On the transition to a new supplier, the filing states Indivior has identified a replacement but notes that its obligations under the new supply agreement will only become enforceable "after validation of the new supplier's manufacturing process." The company further disclosed that the new supplier agreement is not expected to be material to the registrant. The Deed of Variation and Termination was filed as Exhibit 10.1 to the Current Report. Chief Financial Officer Ryan Preblick signed the report on behalf of the registrant.

What Was Disclosed

Indivior Pharmaceuticals disclosed the early termination of its tablet manufacturing supply agreement with Reckitt Benckiser, moving the end date to January 15, 2027, identifying a new supplier, and characterizing associated costs as non-material.